OTCM
NURPF
Market cap1.82bUSD
Oct 20, Last price
14.28USD
Name
Neuren Pharmaceuticals Ltd
Chart & performance
P/E
84.53
P/S
39.80
EPS
0.24
Vol. 1Y
112.08%
Shs. 5Y
4.08%
Rev. 5Y
146.03%
Div Yld LY
—
Div Yld TTM
—
Revenues
65m
-69.69%
Net income
30m
-78.57%
CFO
125m
P
Dividend
Sep 15, 20260.10557 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Key people
Clive Blower
Chief Operating Officer · since 2024
Larry Glass
Chief Science Officer · since 2018
Jonathan Pilcher
Chief Executive Officer, Managing Director, Executive Director · since 2021
Liza Squires
Chief Medical Officer · since 2022
Gerry Zhao
Chief Business Officer · since 2024
Lauren Frazer
Chief Financial Officer, Company Secretary · since 2020
Non-Executive Independent Chairman of the Board · since 2022
Dianne Angus
Non-Executive Independent Director · since 2018
Joseph Basile
Non-Executive Independent Director · since 2023
Non-Executive Independent Director · since 2018
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||